Abstract
You have accessJournal of UrologyProstate Cancer: Localized: Active Surveillance I (MP23)1 Apr 2020MP23-04 THE EXPANSION OF ACTIVE SURVEILLANCE: REFLECTIONS ON ONCOLOGIC OUTCOMES OF THOSE FAILING THIS INCREASINGLY ACCEPTED MANAGEMENT STRATEGY Brennan Timm*, Peter Liodakis, Damien Bolton, Greg Jack, and Nathan Lawrentschuk Brennan Timm*Brennan Timm* More articles by this author , Peter LiodakisPeter Liodakis More articles by this author , Damien BoltonDamien Bolton More articles by this author , Greg JackGreg Jack More articles by this author , and Nathan LawrentschukNathan Lawrentschuk More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000856.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Active surveillance has become the preferred choice of management when compared with surgery or radiotherapy amongst those patients with low volume, low grade prostate cancer. Expansion upon PRIAS criteria defining the appropriate active surveillance population has become commonplace. This change in thinking has ensued as large prospective randomized trials such as PROTECT mature, with 10 year follow up suggesting there is no overall mortality benefit to aggressive therapy versus active surveillance. We sought to ascertain whether those men who fail active surveillance have worse oncologic outcomes than matched peers undergoing immediate radical prostatectomy. METHODS: An audit was undertaken of a prospectively collected database capturing patients with prostate cancer identified by transperineal biopsy between January 2012 and December 2017. Patients were divided into those initially managed by active surveillance vs those with who were treated with surgery primarily. Histologic and oncologic outcomes were compared for time and disease burden matched populations of men with low and low- intermediate risk prostate cancer defined as ISUP 1 and 2 (Gleason pattern 4 component <10%) low volume disease respectively. 128 patients over the 5 year period were captured, where 88 were initially placed on active surveillance, and 40 elected to proceed to radical prostatectomy without a preliminary period of Active Surveillance. RESULTS: Mean patient age was 60.6 vs 61 years in the active surveillance and immediate surgery groups, mean PSA at diagnosis was 5.2 vs 5.6 respectively, and pre biopsy MRI was performed in 71% vs 73% of the AS vs immediate surgery groups. Surgical specimens had a gland volume of 52ml vs 50 ml. 71% of patients had one or more MRI scans during their period of active surveillance. Pathological stage of pT3a was 45% vs 32%, 21% vs 0% had pathological upgrading of Gleason score and 25% vs 17.5% had involved margins in the AS vs immediate treatment groups. Biochemical recurrence with a minimum of 18 months of follow up has been 13% in the AS group vs 0% in the immediate treatment groups. Mean time on active surveillance to failure was 29.1 months. CONCLUSIONS: Those men who fail AS appear to have worse outcomes compared to matched peers undergoing immediate radical prostatectomy. These results are possibly reflective of an increasing trend to put patients on active surveillance who do not meet the strict PRIAS criteria for active surveillance in an effort to delay or avoid potential side effects of treatment of their prostate cancer. Source of Funding: nil © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e338-e339 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Brennan Timm* More articles by this author Peter Liodakis More articles by this author Damien Bolton More articles by this author Greg Jack More articles by this author Nathan Lawrentschuk More articles by this author Expand All Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have